Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607919 · ClinicalTrials.gov registry record · Phase 4
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 209
- Enrollment target
NCT00607919 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 209 participants.
The verdict
NCT00607919, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 209 participants
- Enrollment target
Study Summary
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
Interventions
- DRUG Placebo
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607919
The ClinicalTrials.gov registry entry for NCT00607919 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00607919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607919 about?
NCT00607919 is a clinical study titled "Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia". This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
What is the current status of trial NCT00607919?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 209 participants. The study started on 2008-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00607919?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00607919?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.